• 1
    Kaplan MJ. Management of cardiovascular disease risk in chronic inflammatory disorders. Nat Rev Rheumatol 2009; 5: 20817.
  • 2
    Del Rincon I, O'Leary DH, Freeman GL, Escalante A. Acceleration of atherosclerosis during the course of rheumatoid arthritis. Atherosclerosis 2007; 195: 35460.
  • 3
    Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 13037.
  • 4
    Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30: 3640.
  • 5
    Sodergren A, Stegmayr B, Lundberg V, Ohman ML, Wallberg-Jonsson S. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis 2007; 66: 2636.
  • 6
    Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damas JK. Chemokines in cardiovascular risk prediction. Thromb Haemost 2007; 97: 74854.
  • 7
    Hansson GK. Inflammation, atherosclerosis, and coronary heart disease. N Engl J Med 2005; 352: 168595.
  • 8
    Edwards CJ, Syddall H, Goswami R, Goswami P, Dennison EM, Arden NK, et al. The autoantibody rheumatoid factor may be an independent risk factor for ischaemic heart disease in men. Heart 2007; 93: 12637.
  • 9
    Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009; 48: 1122.
  • 10
    Kim SH, Lee CK, Lee EY, Park SY, Cho YS, Yoo B, et al. Serum oxidized low-density lipoproteins in rheumatoid arthritis. Rheumatol Int 2004; 24: 2303.
  • 11
    Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007; 17: 2538.
  • 12
    O'Neill SG, Giles I, Lambrianides A, Manson J, D'Cruz D, Schrieber L, et al. Antibodies to apolipoprotein A-1, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2010; 62: 84554.
  • 13
    Vuilleumier N, Reber G, James R, Burger D, de Moerloose P, Dayer JM. Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J Autoimmun 2004; 23: 35360.
  • 14
    Vuilleumier N, Charbonney E, Fontao L, Alvarez M, Turck N, Sanchez JC, et al. Anti-apolipoprotein A-1 IgG are associated with high oxidised low-density lipoprotein levels in acute coronary syndrome. Clin Sci 2008; 115: 2533.
  • 15
    Vuilleumier N, Rossier MF, Pagano S, Python M, Charbonney E, Nkoulou R, et al. Anti-apolipoprotein A-1 autoantibody of IgG subtype as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J 2010; 31: 81523.
  • 16
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 17
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 130911.
  • 18
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 19
    Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 2003; 33: 64856.
  • 20
    Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK, Roux-Lombard P, et al. Apolipoprotein A-I inhibits the production of interleukin-1β and tumor necrosis factor-α by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001; 97: 23819.
  • 21
    Bryans TD, Braithwaite C, Broad J, Cooper JF, Darnell KR, Hitchins VM, et al. Bacterial endotoxin testing: a report on the methods, background, data, and regulatory history of extraction recovery efficiency. Biomed Instrum Technol 2004; 38: 738.
  • 22
    Quan H, Luo X, Capizzi T. Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment. Stat Med 2005; 24: 215170.
  • 23
    Furenes EB, Arnesen H, Solheim S, Grogaard HK, Hoffmann P, Seljeflot I. The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina. Thromb Res 2009; 124: 5604.
  • 24
    Jefferis BJ, Whincup P, Welsh P, Wannamethee G, Rumley A, Lennon L, et al. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis 2010; 208: 5576.
  • 25
    Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007; 28: 7118.
  • 26
    Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques: a potential role in acute plaque disruption. Stroke 2000; 31: 407.
  • 27
    Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006; 26: 299307.
  • 28
    Chang YH, Lin IL, Tsay GJ, Yang SC, Yang TP, Ho KT, et al. Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Biochem 2008; 41: 9559.
  • 29
    Tchetverikov I, Lard LR, DeGroot J, Verzijl N, TeKoppele JM, Breedveld FC, et al. Matrix metalloproteinases-3,-8,-9 as markers of disease and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 10949.
  • 30
    Deleuran BW. Cytokines in rheumatoid arthritis: localization in arthritic joint tissue and regulation in vitro. Scand J Rheumatol Suppl 1996; 104: 913.
  • 31
    Ottonello L, Cutolo M, Frumento G, Arduino N, Bertolotto M, Mancini M, et al. Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. Rheumatology (Oxford) 2002; 41: 124960.
  • 32
    Boekholdt SM, Peters RJ, Hack CE, Day NE, Luben R, Bingham SA, et al. IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2004; 24: 15038.
  • 33
    Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, Node K. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol 2008; 124: 31925.
  • 34
    Dorweiler B, Torzewski M, Dahm M, Kirkpatrick CJ, Lackner K, Vahl C. Subendothelial infiltration of neutrophil granulocytes and liberation of matrix-destabilizing enzymes in an experimental model of human neo-intima. Thromb Haemost 2008; 99: 37381.
  • 35
    Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004; 44: 194556.
  • 36
    Quinn K, Henriques M, Parker T, Slutsky AS, Zhang H. Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases. Am J Physiol Heart Circ Physiol 2008; 295: 181724.
  • 37
    Van Leeuwen M, Gijbels MJ, Duijvestijn A, Smook M, van de Gaar MJ, Heeringa P, et al. Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR-/- mice. Arterioscler Thromb Vasc Biol 2008; 28: 849.
  • 38
    Mazor R, Shurtzswirski R, Farah R, Kristal B, Shapiro G, Dorlechter F, et al. Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients. Atherosclerosis 2008; 197: 93743.
  • 39
    Nicholls SJ, Hazen SL. Myeloperoxidase, modified lipoproteins and atherogenesis. J Lipid Res 2009; 50 Suppl: S34651.
  • 40
    Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2001; 21: 8448.
  • 41
    Yamashita H, Ehara S, Yoshiyama M, Naruko T, Haze K, Shirai N, et al. Elevated plasma levels of oxidized low-density lipoprotein relate to the presence of angiographically detected complex and thrombotic coronary artery lesion morphology in patients with unstable angina. Circ J 2007; 71: 6817.
  • 42
    Anselmi M, Garbin U, Agostoni P, Fusaro M, Pasini AF, Nava C, et al. Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques. Atherosclerosis 2006; 185: 11420.
  • 43
    Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 188793.
  • 44
    Matsuura E, Kobayashi K, Koike T, Shoenfeld Y, Khamashta MA, Hughes GR. Oxidised low-density lipoprotein as a risk factor of thrombosis in antiphospholipid syndrome. Lupus 2003; 12: 5504.
  • 45
    Satta N, Dunoyer-Geindre S, Reber G, Fish RJ, Boehlen F, Kruithof EK, et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 2007; 109: 150714.
  • 46
    Stojanovich L. Autonomic dysfunction in autoimmune rheumatic disease. Autoimmun Rev 2009; 8: 56972.
  • 47
    Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, et al. Utility of Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 2006; 8: R186.
  • 48
    Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic disease. Vasc Health Risk Manag 2008; 4: 60514.